Cai Jing Wang·2025-10-27 07:44Core Viewpoint - WuXi AppTec (603259) is focusing on its CRDMO (Contract Research, Development, and Manufacturing Organization) business model by divesting its 100% stakes in Kangde Hongyi and Jinshi Pharmaceutical for a base transfer price of RMB 2.8 billion, aiming to enhance its global capabilities and production capacity [1] Group 1: Transaction Details - The divestiture involves a transfer of 100% equity stakes in Kangde Hongyi and Jinshi Pharmaceutical to a newly established company by Hillhouse Capital through its private equity fund [1] - The transaction is aligned with WuXi AppTec's strategy to concentrate on drug discovery, laboratory testing, and process development and manufacturing services [1] Group 2: Financial Impact - The target companies generated approximately RMB 1.16 billion in total revenue from January to September 2025, accounting for about 3.5% of WuXi AppTec's total revenue for the same period [1] - The net profit of the target companies for the same period is approximately RMB 90 million, representing about 0.7% of WuXi AppTec's net profit [1]